NL – Boston Scientific v. Cook

Posted: June 20th, 2022

Boston Scientific Limited and Boston Scientific Medical Device Limited v. Coot Europe Finance B.V., Cook Nederland B.V., Cook Medical Nederland B.V., Cook Ireland Limited, Cook Medical Europe Limited, Cook Medical EMEA Group Limited and Cook France Sarl, District Court Amsterdam 3 May 2022, Case no. C/13/713/564 / KG ZA 22-118 Recently a judgment has been […]


EPLAW – UPC Webinar: Jurisdictional Issues

Posted: June 15th, 2022

Last Tuesday EPLAW Hosted its next webinar in its webinar series dedicated to the UPC. In this webinar, questions regarding Jurisdictional Issues were addressed. Speakers were Julia Ericsson (Sandart and Partners, SE), Pierre Véron (Pierre Véron, FR) and Myles Jelf (Bristows, UK) Questions that were explored at the session were: – What can the new […]


NL – Barco v. Sahara

Posted: June 9th, 2022

Barco N.V. v. Sahara Presentation Systems PLC, District Cout The Hague, 1 June 2022, Case No. HA ZA 19-503 Barco holds EP ‘668 for an ‘Electronic tool and methods for meetings’and markets a presentation system under de name ‘ClickShare’ that incorporates the EP ‘668 technology. ClickShare enables participants to a meeting to share images and […]


IT – Garbuio v. Comas / Infringement by equivalents

Posted: June 2nd, 2022

The Italian Supreme Court on patent infringement by equivalents: central relevance must be given to the individual elements claimed by the patent By judgment no. 120 on 4th January 2022, the Italian Supreme Court addressed the topic of patent infringement by equivalents. In particular, the Court provided guidance on two debated issues under Italian law: […]


News – Book: A Practitioner’s Guide to the Unified Patent Court and Unitary Patent

Posted: May 24th, 2022

The book: “A Practitioner’s Guide to the Unified Patent Court and Unitary Patent” , authored by Paul England is scheduled to be published by Bloomsbury in November 2022 From the blurb: “A Practitioner’s Guide to the Unified Patent Court and Unitary Patent provides practical and detailed advice on all aspects of the system for those […]


NL – Bristol-Myers Squibb v. Sandoz / Apaxiban

Posted: May 19th, 2022

Bristol-Myers Squibb Holdings Ireland Unlimited Company v. Sandoz B.V., District Court The Hague (interlocutory decision), 10 May 2022, Case no.  ECLI:NL:RBDHA:2022:4385 BMS markets the medicine Eliquis®, with apixaban as the active ingredient. Apixaban is a substance that inhibits the action of factor Xa. Inhibiting factor Xa helps prevent blood clots from forming. Eliquis® is used […]


IT – Novartis Pharma v. Medac Farma

Posted: May 5th, 2022

Novartis Pharma vs. Medac Farma, Court of Milan, 10 January 2022, Case number 11933/2022 A decision on second medical use patent and skinny labelling in Italy was handed down by the Court of Milan on 10 January 2022. The Court held skinny label alone as insufficient to avoid infringement of second medical use claims and […]


CJEU – Phoenix v. Harting

Posted: April 29th, 2022

Preliminary ruling under Article 267 TFEU in the case between Phoenix Contact GmbH & Co. KG v. HARTING Deutschland GmbH & Co. KG, Harting Electric GmbH & Co. KG, 28 April 2022, Case No. C‑44/21, ECLI:EU:C:2022:309 “By its question, the referring court asks, in essence, whether Article 9(1) of Directive 2004/48 must be interpreted as […]


EPLAW – YOUNG EPLAW 2022 Annual Congress

Posted: April 26th, 2022

After a three year covid-related hiatus, the Young EPLAW event finally took place in person again in Brussels yesterday. The event was preceded by a mock trial and a social event on Sunday. The program was busy and varied, with topics ranging from ‘Hot topics in FRAND litigation’ to ‘Confidentiality in court proceedings’ ,  ‘Cross […]


NL – Novartis v. Mylan

Posted: April 20th, 2022

Novartis versus Mylan, PI judge District Court of The Hague 22 March 2022, ECLI:NL:RBDHA:2022:2490 (interlocutory decision) Market entry by the generic pharmaceutical company Mylan before the grant of a Novartis patent – which will be infringed once granted – is not unlawful. Not even if Novartis’ patent will be granted with certainty and the wording […]